



FEDERAL MINISTRY OF HEALTH AND SOCIAL WELFARE

DEPARTMENT OF PUBLIC HEALTH

**NATIONAL TUBERCULOSIS, LEPROSY & BURULI ULCER
CONTROL PROGRAMME**

**Country Experiences Providing a National Perspective on
Implementation of Treatment Decision Algorithms**

Dr. Urhioke Ochuko

Head, Child and Adolescent TB Unit, NTP Nigeria

International Webinar on Paediatric and Adolescent TB

26th June, 2025


Outline

- Background
- Treatment Decision Algorithms Adaptation Process
- Operational Research Component - VEDUTA Study
- National TB Notification Trend
- Lessons Learned
- Next Steps




Background

- Low child TB notification - a major challenge in Nigeria
- In 2022, only 35% of the estimated 58,000 children with TB notified
- Objective 3 of TB National Strategic Plan - enhance child TB detection and treatment
- Limited success with interventions to improve TB detection in children



Treatment Decision Algorithms Adaptation Process

- New paediatric TB guidelines/operational handbook by WHO in February 2022
- National paediatric TB technical working group meeting in March 2022
 - Adapted the use of the Treatment Decision Algorithms (TDAs) A and B for pulmonary TB diagnosis
- Rapid advice on new WHO recommendations on paediatric TB published in July 2022
- Dissemination of rapid advice to States/partners



Operational Research Component - VEDUTA Study



- WHO's call for external validation of TDAs → VEDUTA study

Primary objective:

- Evaluate performance of the TDAs against 'standard definition'

Secondary objectives:

- Determine feasibility, acceptability and impact of TDAs use on TB notification



Methodology

Study design: A mixed multi-centre interventional single-arm diagnostic evaluation study

Population:

- Children < 10 years old with presumptive TB visiting healthcare facilities
- Healthcare workers (HCWs) in sites who used the TDAs more than 10 times

Settings and study sites:

- 5 States (Kaduna, Oyo, Borno, Enugu, Cross River and Federal Capital Territory (FCT))
- 24 sites with 12 secondary/tertiary and 12 primary healthcare facilities

Sample size: 1,037 children

Enrollment period: November 2023 - April 2024



Methodology 2

- The TDAs (A—with and B—without CXR) were evaluated in 12 tertiary/secondary and 12 primary healthcare facilities, across 5 States and FCT
- A two-month follow-up period allowed for classification of cases against a standard definition (derived from Graham *et al.*, CID 2015).
- HCWs survey to determine acceptability and feasibility of TDAs use
- A before/after comparison of TB notification was reported in 19 VEDUTA research sites. Data were extracted from the programmatic reports.



Specificity and Sensitivity of the TDAs

Sensitivity (Se), specificity (Sp), positive/negative predictive value (PPV/NPV) of the WHO TDA A and TDA B in the VEDUTA study; N=1,037								
	TDA A				TDA B			
MITT (N=1,037)	Clinician initial decision	Modified Standard definition		Total	Clinician initial decision	Modified Standard definition		Total
		TB	Not TB			TB	Not TB	
	TB	186	0	186	TB	150	1	151
	Not TB	29	291	320	Not TB	20	360	380
	Total	215	291	506	Total	170	361	531
	Se= 86.5%; CI _{95%} [81.2; 90.8]				Se= 88.2%; CI _{95%} [82.4; 92.7]			
	Sp= 100.0%; CI _{95%} [98.7; 100.0]				Sp= 99.7%; CI _{95%} [98.5; 100.0]			
	PPV= 100.0%; CI _{95%} [98.0; 100.0]				PPV= 99.3%; CI _{95%} [96.4; 100.0]			
	NPV= 90.9%; CI _{95%} [87.2; 93.8]				NPV= 94.7%; CI _{95%} [92.0; 96.8]			
	Clinician decision: clinician initial decision to treat or not for TB based on TDAs as per protocol							
Standard definition for this preliminary analysis: derived from Graham et al. J Infect Dis. 2012 & CID. 2015, reviewed with health outcomes and treatment reported at month 2, and by independent national experts for lost-to-follow-up and deceased cases								
MITT: " Modified Intention to Treat Study Population " analysis: Confirmed TB + (unconfirmed TB + unclassifiable) (= TB) versus unlikely (= not TB)								

Both A & B TDAs had a **specificity of 99.9%** and **sensitivity of 87.4%** in our first overall analysis


Feasibility and Acceptability by HCWs

- 34 respondents: 21 were female and 19 were ≥ 45 years old
- Mainly doctors (9/34), nurses (7/34) and community health workers (12/34)
- 12/34 worked in primary healthcare facilities
- All respondents agreed the TDAs provided **timely guidance**
- Four out of five respondents would **strongly recommend** TDAs use to other colleagues and facilities



Impact of TDA Utilization on TB Notification

Average TB notifications across 19 research sites before (November 2021/2 – April 2022/3) and during (November 2023 – April 2024) recruitment period for the VEDUTA study




No of TB notifications increased:


- From **113** childhood TB notified on average over a 6-month period to **405** (during same length intervention period) in the **0-9 years** old category
- Slightly increased for the other age categories

National TB Notification Trend


National Trend in TB Notification




Child TB Notification Trend




Child DR-TB Notification Trend



2024 Child TB Disaggregation by States



2024 Child TB Disaggregation by Age



Lessons Learned

- TDAs can bridge TB case detection gap in children
- Task shifting of paediatric TB diagnosis to nurses/community health extension workers feasible
- HCWs training and re-training is key
- Regular sensitization of stakeholders on use of TDAs
- Provision of Standard operating procedures on the TDAs
- Need to simplify some terminologies on TDAs e.g., tachypnoea, tachycardia



Next Steps

- Two manuscripts on VEDUTA study in progress
- Full adoption of the TDAs
- Scale up nation-wide use of TDAs
 - Printing of SOPs for TDAs use
 - Training of HCWs on TDAs use
 - Continuous sensitization of TB partners
- Implementation research on digitizing the algorithms.



Acknowledgements

- The VEDUTA study was funded by TDR through a grant from USAID
- The research package TDA4Child was adapted for the development of the VEDUTA project (<https://tdr.who.int/tuberculosis-research/TDA4Child-initiative>)
- We acknowledge the contributions of:
 - United States Government
 - TDR
 - Global Fund
 - WHO Country Office (Nigeria)
 - Damien Foundation of Belgium
 - KNCV International Cepheid Project (Nigeria)
 - All TB Partners in Nigeria



Thank you

**Information: urhioke.ochuko@gmail.com
website: www.ntblcp.org.ng**